These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 29262504

  • 1. [Expressions and clinical significances of paired box gene 2 and cyclin D1 in advanced ovarian serous carcinoma].
    Song Y, Zuo J, Huang X, Shen GH, Liu XY, Zhang X.
    Zhonghua Zhong Liu Za Zhi; 2017 Dec 23; 39(12):891-895. PubMed ID: 29262504
    [Abstract] [Full Text] [Related]

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct 25; 52(10):687-696. PubMed ID: 29060967
    [Abstract] [Full Text] [Related]

  • 3. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX, Yu L, Bi R, Yang WT.
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug 25; 40(8):511-6. PubMed ID: 22169637
    [Abstract] [Full Text] [Related]

  • 4. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE, Fathy A, Elsebai EA, Nawar N, Etman WM.
    Ann Diagn Pathol; 2018 Aug 25; 35():27-37. PubMed ID: 30072015
    [Abstract] [Full Text] [Related]

  • 5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr 25; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
    Song Y, Huang X, Shen GH, Liu XY, Zhang X.
    Zhonghua Zhong Liu Za Zhi; 2017 Jun 23; 39(6):424-428. PubMed ID: 28635231
    [Abstract] [Full Text] [Related]

  • 7. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
    Zhang J, Wang JC, Li YH, Wang RX, Fan XM.
    Chin Med J (Engl); 2017 Feb 05; 130(3):280-287. PubMed ID: 28139510
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U, Denkert C, Braicu I, Sehouli J, Dietel M, Loibl S, Darb-Esfahani S.
    Virchows Arch; 2017 Feb 05; 470(2):143-151. PubMed ID: 27913862
    [Abstract] [Full Text] [Related]

  • 9. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
    Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK.
    Mod Pathol; 2009 Sep 05; 22(9):1243-50. PubMed ID: 19525924
    [Abstract] [Full Text] [Related]

  • 10. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
    Wang M, Ma H, Pan Y, Xiao W, Li J, Yu J, He J.
    Appl Immunohistochem Mol Morphol; 2015 Apr 05; 23(4):280-7. PubMed ID: 24992169
    [Abstract] [Full Text] [Related]

  • 11. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.
    Wu GQ, Xie D, Yang GF, Liao YJ, Mai SJ, Deng HX, Sze J, Guan XY, Zeng YX, Lin MC, Kung HF.
    Int J Cancer; 2009 Dec 01; 125(11):2631-42. PubMed ID: 19672860
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H.
    Int J Gynecol Pathol; 2008 Jul 01; 27(3):380-9. PubMed ID: 18580315
    [Abstract] [Full Text] [Related]

  • 13. The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study.
    Wang X, Fu Y, Chen X, Ye J, Lü B, Ye F, Lü W, Xie X.
    J Cancer Res Clin Oncol; 2010 Jul 01; 136(7):989-96. PubMed ID: 20091184
    [Abstract] [Full Text] [Related]

  • 14. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.
    Clin Cancer Res; 2004 Aug 01; 10(15):5168-77. PubMed ID: 15297421
    [Abstract] [Full Text] [Related]

  • 15. [Expression and role of glucose-regulated protein 78 in ovarian serous adenocarcinoma].
    Fan LM, Su J, Dong H, Wei M, Cui MH.
    Zhonghua Yi Xue Za Zhi; 2013 Mar 05; 93(9):659-62. PubMed ID: 23751742
    [Abstract] [Full Text] [Related]

  • 16. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
    Milea A, George SH, Matevski D, Jiang H, Madunic M, Berman HK, Gauthier ML, Gallie B, Shaw PA.
    Mod Pathol; 2014 Jul 05; 27(7):991-1001. PubMed ID: 24336157
    [Abstract] [Full Text] [Related]

  • 17. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
    Wang A, Lu L, Wang Y, Sun Y, Zhang Y, Guo C, Gu Y, Liu A.
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan 05; 43(1):20-4. PubMed ID: 24713244
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H.
    Hum Pathol; 2019 Mar 05; 85():299-308. PubMed ID: 30428389
    [Abstract] [Full Text] [Related]

  • 19. [Relationship between P53 Protein Expression and Prognosis of Advanced Ovarian Serous Adenocarcinoma].
    Zuo J, Song Y, Li Z, Wu LY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Apr 05; 38(2):169-74. PubMed ID: 27181893
    [Abstract] [Full Text] [Related]

  • 20. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M, Dawson A, Kim H, Lam N, Russell H, Bruce M, Bittner M, Hoenisch J, Scott SA, Talhouk A, Chiu D, Provencher D, Nourmoussavi M, DiMattia G, Lee CH, Gilks CB, Köbel M, Carey MS.
    Gynecol Oncol; 2020 Apr 05; 157(1):12-20. PubMed ID: 31954537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.